Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US9125859B2 · kind B2 · utility
70Cited by
1References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 30, 2011 |
| Grant date | Sep 8, 2015 |
| Priority date | — |
| Expiry date | Oct 22, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.